AV-COVID-19
- Generic Name
- AV-COVID-19
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
AV-COVID-19 is a vaccine composed of autologous dendritic cells loaded with SARS-CoV-2 antigens and with or without Granulocyte-macrophage colony-stimulating factor (GM-CSF).
The vaccine is created from the receiving patients’ isolated peripheral blood monocytes. The monocytes are then differentiated in vitro into dendritic cells with IL-4 and GM-CSF, incubated with SARS-CoV-2 antigens prior to administration.
The vaccine was developed and tested by Aivita Biomedical, Inc.. As of July 2020, the company is pursuing an adaptive Phase IB-II Randomized Clinical Trial (NCT04386252) to test the vaccine.
- Associated Conditions
- -
- Associated Therapies
- -
A Study of Daclatasvir and Sofosbuvir With Ribavirin in Subjects With Cirrhosis and Genotype 3 Hepatitis C Infection
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 106
- Registration Number
- NCT02673489
- Locations
- 🇺🇸
Northeast Clinical Research Center, Bethlehem, Pennsylvania, United States
🇺🇸Bon Secours St. Mary's Hospital of Richmond, Inc, Richmond, Virginia, United States
🇺🇸University Gastroenterology, Providence, Rhode Island, United States
Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- ViiV Healthcare
- Target Recruit Count
- 12
- Registration Number
- NCT02082808
- Locations
- 🇺🇸
GSK Investigational Site, Overland Park, Kansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.